Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascentage to Start China Trials of Bcl-2 Apoptosis Candidate

publication date: Nov 23, 2020

Suzhou Ascentage Pharma said its novel Bcl-2 inhibitor was approved to start two China Phase Ib/II clinical trials: one in Waldenström macroglobulinemia (WM), and the other one in multiple myeloma (MM). APG-2575 is designed to treat hematologic malignancies by selectively blocking Bcl-2 to restore the normal apoptosis process in cancer cells. The candidate has started multiple trials in China and Australia. The WM Phase Ib/II trial will be a global multicenter test with centers in Australia, China and the US. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.